TCF3 and Burkitt lymphoma: These include ID3, a negative regulator of TCF3/E2A that is inactivated in 35-58% of all BL subtypes, and TCF3, which encodes the transcription factor E2A and is targeted by gain-of-function mutations in 10-25% of cases (68–70).